Amgen's Repatha Gets Big Formulary Win With CVS Health
This article was originally published in The Pink Sheet Daily
Executive Summary
Evolocumab will be the only PCSK9 inhibitor on the PBM's commercial formulary, with Amgen agreeing to provide additional pricing discounts based on outcomes and utilization.
You may also be interested in...
Medicare Risk-Sharing Contracts: A More Feasible Drug Cost Solution?
Duke’s Mark McClellan made a strong pitch for such contracting during a Capitol Hill debate on cost control with Johns Hopkins’ Gerard Anderson.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.